News and reporting on prostate cancer.
In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
A University of Michigan-led team found that the lncRNA ARLNC1 forms a feedback loop with the androgen receptor to promote progression in prostate cancer.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
The method uses hydrogel encapsulation, which mimics a tissue sample, in order to allow circulating tumor cell isolation and extraction through laser dissection.
At least half a dozen cancer phenotypes showed significant associations with GWAS variant-based polygenic risk scores in a new phenome-wide association study.
GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
Test volume and revenues increased in the US, especially in prostate cancer. Meanwhile, international test volume was down but corresponding revenue increased.
In Cell this week: genome sequencing analysis of Egyptian bat, "chemistry-first" approach to find personalized lung cancer treatment targets, and more.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.